ENROLL NOW: CLINICAL TRIAL FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Today, the End Brain Cancer Initiative (EBCI) and I want to make you aware of a clinical trial, The PROSPECT Study, that is enrolling for a type of LYMPHOMA known as Primary Central Nervous System Lymphoma or PCNSL.
PROSPECT is an open-label, Phase II study that is evaluating the efficacy, safety and pharmacokinetics of an oral medicine called tyrosine kinase (BTK) inhibitor in patients with PCNSL as currently there are no medications FDA approved in the U.S. specifically for the treatment of this disease. About 112 patients will be enrolled in this trial in the U.S.
To learn more, please go to www.EndBrainCancer.org, review our web landing page for the PROSPECT trial, sponsored by Ono Pharma USA, Inc. and fill out our “Advocacy & Patient Inquiry” form so that we can call and email you with additional information as well as “Directly Connect” you to the site and doctor that has this trial open/enrolling closest to where you live in the U.S. Some sites that are currently enrolling for this trial are:
City of Hope - Comprehensive Breast Cancer Center - Duarte, CA
Contact: Avyakta Kallam | 626-218-8276 | akallam@coh.org
University of California - Irvine, CA
Contact: Daniela Bota | 714-456-7214 | dbota@hs.uci.edu
Stanford University - Palo Alto, CA
Contact: Neel Gupta | 650-7245361 | neelkg@stanford.edu
University of Colorado Denver - Aurora, CO
Contact: Denise Damek | 720-848-8312 | denise.damek@ucdenver.edu
Yale Cancer Center - New Haven, CT
Contact: Antonio Omuro | 475-202-3955 | antonio.omuro@yale.edu
Additional Information on this clinical trial can also be found here: https://clinicaltrials.gov/study/NCT04947319?id=NCT04947319&rank=1
Blessings,
Dellann Elliott Mydland
President & CEO
The EndBrainCancer Initiative | Chris Elliott Fund
16150 NE 85th St #201
Redmond WA 98052
